Patrón de uso de los nuevos antidepresivos en la práctica clínica

Actas Espanolas de Psiquiatria

Volumn 26, Issue 2, 1998, Pages 75-82

  Montejo, A L ^a   Gilaberte, I ^b,d   Fombellida, C ^a   Hylan, T R ^c   Sacristan J A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b DCRandT   (Spain)

^c ELI LILLY AND COMPANY   (United States)

^d Depto de Invest Clínica   (Spain)

Author keywords

Effectiveness; Naturalistic studies; New antidepressants; Pattern of use

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; DEPRESSION; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 3042978624     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sacristan JA, Soto J, Galende I, Hylan TR. A review of methodologies for assessing drug effectiveness and a new proposal: randomized database studies. Clin Ther 1997;19:1510-7.
2. Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Managed Care 1997;3:323-30.
3. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197-202.
4. Ansseau M, Gabriels A, Loyens J, et al. A double-blind comparison of paroxetine and fluvoxamine in major depression. Eur Neuropsychopharmacol 1993;3: 323-4.
5. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-5.
6. Latimer PR, Ravindran AV, Bernatchez JP, et al. Sertraline vs. Fluoxetine treatment in major depression. Poster presented at X Congress of World Psychiatric Association. Madrid; 1996.
7. Patris M, Bouchard JM, Bougeral T, et al. Citalopram vs. Fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
8. Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow-up study. J Serotonin Research 1996;4: 267-70.
9. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiology and Drug Safety 1997;6:235-46.
10. Arias F, Padin JJ, Gilaberte I, et al. Comparative tolerability among the different selective serotonin reuptake inhibitors and venlafaxine in a naturalistic setting. In press.
11. Thompson D, Buesching D, Gregor K, et al. Patterns of antidepressant use and their relations to costs of care. Am J Managed Care 1996;2 (9):1239-46.
12. Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 1997;11:464-72.
13. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997;48:1420-7.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15. Guy W. ECDEU Assessment Manual of Psychopharmacology, US Department of Health, Education, and Welfare publication ADM 76-338. Rockville, MD: National Institute of Mental Health 1976;217-22.
16. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry 1992;53(8, suppl):32-44.
17. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B34:187-220.
18. Greene WH. Econometric Analysis. New York: Macmillan; 1995.
19. Rosholm JU, Gram L. Outpatient utilization of antidepressants: a prescription database analysis. J Affect Disord 1993;27:21-8.
20. Donoghue JM, Wildgust H. Cross-sectional database analysis of antidepressant prescribing in general practice in United Kingdom. BMJ 1996;313:811-2.
21. Lin EH, Von Korff M, Katon W, et al. The role of primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
22. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
23. Katzelnick DJ, Kobak KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996;31:374-388.
24. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51:60-9.
25. MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1997;313:860-1.
26. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-96.
27. Sclar DA, Robinson LM, Skaer T, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
28. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressant for treating depressed patients in the California Medicaid (Medi-Cal) program. Int Clin Psychopharmacol 1998; in press.
29. Navarro R, Valler WE, Samgle M. Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings. Med Interface 1995;8(8):11-119.
30. Gregor K, Overhage JM, Coon SJ, et al. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther 1994;16(2):306-15.
31. Gregor K, Riley JA, Downing DK. Concomitant use of anxiolytic and hypnotics with selective serotonin reuptake inhibitors. Clin Ther 1996;18(3);521-7.
32. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995;17:786-90.
33. Geretsegger C, Böhmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994;9: 25-9.
34. Martínez J, de Abajo FJ Tratamiento de la depresión en atención primaria. Información Terapeútica del Sistema Nacional de Salud 1994;18:33-41.
35. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacol 10(Suppl 2):15-20.
36. Bourgeois. Review of clinical use of sertraline by family practice physicians in a small Air Force hospital. Military Med 161(7):425-7.
37. Ekselius L, von Knorring L, Eberhard G. A double-blind comparing sertraline and citalopram in patients with major depression treated in general practice. Eur Neuropsychopharmacol 1997;7(2):S147.
38. Wernicke JF, Bosomworth JC, Ashbrook E. Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 4(Suppl 1):63-7.
39. Simon GE, Von Korff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15 (6):399-408.
40. Bingefors K, Isacson D, von Knorring L. Antidepressant dose patterns in swedish clinical practice. Int Clin Psychopharmacol 1997;12:283-90.
41. Hylan TR, Meneades L, Crown WH, et al. Patterns of antidepressant use and their relation to clinical outcomes. J Affect Disord 1998 (in press).
42. Sacristan JA, Gilaberte I, Montejo AL, Crown WH, Hylan TR. Un estudio naturalista sobre la utilización de antidepresivos y su repercusión económica en la práctica clínica habitual. Enviado a publicación.